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The clinical use of medical induction of ovulation in normogonadotrophic anovulatory women (WHO II), including
polycystic ovary syndrome, is increasingly questioned. However, we believe that this treatment modality still repre-
sents a highly effective means of fertility treatment in women with low pregnancy chances without intervention. A
conventional treatment algorithm involving clomiphene citrate (CC) followed by FSH induction of ovulation may
result in a 71% cumulative singleton live birth rate. In attempts to improve treatment outcome further and reduce
complication rates, new compounds such as insulin-sensitizing agents or aromatase inhibitors are currently used
increasingly. Approaches such as patient selection for different treatment modalities on the basis of initial screening
characteristics and alternative protocols for FSH ovulation induction may also be proposed to render treatment
algorithms more patient tailored and therefore improve overall outcomes. More research is needed in this area,
rather than referring these patients to assisted reproduction prematurely. This may lead to a more individually
tailored approach for ovulation induction in a given patient, resulting in a further improvement of the balance
between chances for success versus complications.
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Classic induction of ovulation strategies [clomiphene citrate
(CC) followed by FSH injections] in patients with normogo-
nadotrophic anovulation (World Health Organization, 1993;
ESHRE Capri Workshop Group, 2003) can be experienced as a
time-consuming and ineffective treatment modality with high
complication rates. To deal with this, patients are increasingly
offered `controlled' ovarian stimulation combined with intra-
uterine insemination or IVF as ®rst-line treatment, regardless
of the type of infertility (Homburg and Insler, 2002). This
alteration in treatment strategy is not based on sound scienti®c
evidence and is likely to result in substantially higher multiple
pregnancy rates and a major increase in overall treatment costs.
The objective of this debate is, in response to treatment strategy
alterations as mentioned above, to discuss the ef®cacy and
ef®ciency of current ovulation induction strategies and point
out possibilities for improvement.
In a prospective follow-up study, starting in 1993, of 240 WHO
II patients in our fertility clinic, effectiveness of the approach
of classical ovulation induction (CC as ®rst-line, exogenous
FSH as second-line treatment) was evaluated (Imani et al.,
2002a; Eijkemans et al., 2003). Initial treatment with CC
(highest daily dose of 150 mg for a maximum of six cycles)
resulted in ovulation in 77% of all patients. A pregnancy
occurred in 47% of all patients and in 61% of ovulatory
patients (cumulative singleton live birth rate 41% and multiple
live birth rate 2%). Both chances for ovulation (Imani et al.,
1998, 2000) and pregnancy (Imani et al., 1999) may be
predicted on the basis of initial screening characteristics such
as age, body mass index (BMI = weight/height2), free androgen
index [(FAI = testosterone 3 100/sex hormone-binding
globulin (SHBG)], cycle history and polycystic ovaries.
Subsequently, second-line FSH induction of ovulation in our
study population failing to ovulate or conceive after CC
resulted after a mean of 3.5 stimulation cycles in an ovulation
rate of 82%, a cumulative pregnancy rate of 56%, a singleton
live birth rate of 43% and a multiple live birth rate of 5%
(Mulders et al., 2003a). Overall, treatment outcome in our
study population resulted in a cumulative singleton live birth
rate of 71% after `classical' ovulation induction using CC
followed by exogenous FSH (Eijkemans et al., 2003). The
remaining group was exposed to IVF, resulting in a live birth
rate of 40% after a maximum of three cycles (Mulders et al.,
2003b).
Efforts to enhance ef®ciency and safety of FSH ovulation
induction treatment include the use of new gonadotrophin
preparations, alternative treatment dose regimens and predic-
tion models (ESHRE Capri Workshop Group, 2003). Initial
patient characteristics may be able to predict chances of
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treatment response and outcome of both CC and FSH ovulation
induction. In this way, it may also be possible to identify
women who would bene®t from alternative treatment algo-
rithms, including ®rst-line treatment with insulin-sensitizing
drugs (Lord et al., 2003), aromatase inhibitors (Mitwally and
Casper, 2003) or ovarian drilling (Farquhar et al., 2001;
Pirwany and Tulandi, 2003). For these new treatment
modalities, it can be concluded that, although initial studies
are promising, their role in everyday clinical practice remains
uncertain until data from prospective follow-up studies become
available regarding large series of well de®ned patient groups.
A major dif®culty associated with FSH ovulation induction
is the individual variability in ovarian response to a given dose.
Treatment regimens which involve a stepwise increase in low
dosages of gonadotrophin during follicular development (`step-
up' regimens) are now in common clinical use. The conven-
tional step-up regimen employed relatively high initial doses of
gonadotrophins. While ovulation rates of 70% were achieved,
multiple pregnancy rates were observed to occur in 36% of
pregnancies, and the potentially life-threatening ovarian
hyperstimulation syndrome (OHSS) in 14% (Dor et al.,
1980). The subsequently introduced `low-dose, step-up' regi-
men is associated with considerably lower complication rates
(White et al., 1996), and this regimen is now employed in most
European centres. Studies of the endocrine physiology of
normal follicular development have highlighted the essential
unphysiological nature of step-up regimens (van Santbrink
et al., 1995a). In an attempt to mimic physiology more closely
in anovulatory women, a stimulation regimen has been
developed which involves reducing (instead of increasing)
the dose of gonadotrophins administered during the period of
follicular development (van Santbrink and Fauser, 1997). This
`low-dose, step-down' regimen has proven itself as a reliable
clinical tool for the induction of ovulation in our tertiary
referral centre, although monitoring of a step-down cylcle may
need more experiece and skills compared with a low-dose,
step-up regimen (van Santbrink et al., 1995b). In a small
prospective randomized trial, the low-dose, step-down and the
low-dose, step-up regimen gave comparable clinical outcomes.
However, in the step-down group, a substantially reduced
stimulation period was required with a more physiological late-
follicular FSH serum pro®le. This resulted in more mono-
follicular stimulation cycles, coinciding with more cycles in
which estradiol (E2) serum levels were within the physiological
range (van Santbrink and Fauser, 1997). As we know, multi-
follicular growth and high late follicular phase E2 serum levels
are associated with increased multiple gestation rates and
higher chances for ovarian hyperstimulation (Haning et al.,
1983; Blankstein et al., 1987)
In a recently published randomized multi-centre study
reported in this journal, comparing a low-dose, step-up versus
a step-down gonadotrophin protocol in polycystic ovary
syndrome (PCOS) (Christin-Maitre et al., 2003), 83 patients
were included over an extended period of time in 11 centres.
This, again emphasizes how dif®cult it currently is to execute
these kind of studies with suf®cient patient numbers. It strongly
suggests that many PCOS patients are indeed treated differ-
ently. Patients included in the study presented with oligo-
amenorrhea, normal BMI (23.5 6 4.4 kg/m2), no signs of
hyperandrogenism (testosterone < 1 ng/ml) and sonographic
mild polycystic ovary (PCO) criteria. Hence, this seems like a
group with potentially favourable ovulation induction out-
come, since overweight and hyperandrogenaemia are clearly
associated with poor ovulation induction results, as discussed
earlier. Treatment results showed a relatively high cancellation
rate (38% versus 15%) in the step-down compared with the
step-up group, but a similar overall ovulation rate (62% versus
70%). Pregnancy rates were comparable, but there was a clear
tendency for hyperstimulation in the step-down group (multi-
follicular growth and high serum E2 concentrations). These
®ndings are not surprising considering that a step-down
protocol with a starting dose of 100 IU was applied to an
unselected, mild (or non) PCOS population. Most of these
patients can be expected to be good responders to FSH
stimulation, i.e. low FSH response dose (Imani et al., 2002b).
Chances for multiple follicle development during FSH induc-
tion of ovulation may be predicted by a model in which initial
serum androstenedione (AD), ovarian response during preced-
ing CC treatment and number of antral follicles upon initial
screening are represented (van der Meer et al., 1998; van
Santbrink et al., 2002; Jonard et al., 2003; Mulders et al.,
2003c). As multiple follicle growth is associated with chances
for OHSS and multiple pregnancy (Blankstein et al., 1987),
patients at risk may be identi®ed using this prediction model.
Study data (Christin-Maitre et al., 2003) con®rm this conten-
tion since at least 55±73% of the patients randomized for the
step-up protocol did not need a dose increase to develop a pre-
ovulatory follicle.
Accordingly, in our selected (tertiairy referral) study popu-
lation, 31% of the patients developed a pre-ovulatory follicle
without a dose increase in the low-dose, step-up protocol
(E.J.P.van Santbrink, unpublished) (see also Table I). These
patients were shown to be good responders to the initial starting
dose of gonadotrophins. Evaluation of late follicular phase
characteristics of similar patients demonstrated a decremental
FSH serum pro®le close to physiology, probably due to the
negative feedback of the growing follicle on pituitary FSH
release (Schoot et al., 1992; van Santbrink and Fauser, 1997). It
may be proposed, as reported earlier, that these women would
hyper-respond in cases where a step-down regimen was offered
with a relatively high starting dose, resulting in increased
chances for treatment complications. In an attempt to avoid
this, new patients for induction of ovulation with gonadotro-
phins are currently offered ®rst a `dose-®nding' low-dose, step-
up induction cycle in our centre, in which the FSH response
dose is determined (Imani et al., 2002b). After that, step-down
induction cycles are applied with a starting dose 37.5 IU above
the effective response dose in the initial low-dose, step-up
cycle. A ®xed dose is applied in the following cycle if the
patient responded with suf®cient follicle growth in response to
the starting dose during the dose-®nding ®rst low-dose, step-up
induction cycle. Treatment results of the dose-®nding low-dose
step-up cycle and following step-down induction cycle are
shown (Table I). Comparing the results of ovulation induction
of the multi-centre trial (Christin-Maitre et al., 2003) with the
results in our sequential low-dose step-up followed by step-
E.J.P.van Santbrink and B.C.J.M.Fauser
2500
down treatment group (E.J.P.van Santbrink, unpublished
observations), it can be concluded that the low-dose step-up
results show comparable monofollicular development rates,
ovulation rates and (ongoing) pregnancy rates (see Table I). In
addition, the step-down results are also comparable except for
the monofollicular development rates (32% versus 50%). It
should be noticed that patient characteristics in both step-down
populations are very different. Substantially more severe PCOS
characteristics (obesity, hyperandrogenism and more frequent
PCO ovaries) are found in the low responder group (Mulders
et al., 2003a) compared with good responders. A recent
systemic review regarding patient characteristics predicting
ovulation induction outcome could con®rm these ®ndings
(Mulders et al., 2003a).
A new approach to prevent hyperstimulation in gonado-
trophin ovulation induction due to a starting dose far above the
FSH threshold may be to determine the individual effective
FSH starting dose using a prediction model. Time-consuming
low-dose increments may be overcome by starting with a
higher dose in women with an augmented FSH threshold. It
may also reduce chances for hyper-response in women with a
low FSH threshold. Initial patient and treatment characteristics
(BMI, ovarian response during preceding CC therapy, insulin-
like growth factor 1 and basal FSH) may be able to predict the
individual response to FSH (Imani et al., 2002b). Obviously,
more widespread clinical use of these predictors awaits
external validation of the developed model.
In conclusion, it can be proposed that: (i) it is more dif®cult
to induce ovulation in patients with more severe PCOS criteria
(overweight, hyperandrogenaemia and with polycystic ovar-
ies); (ii) an FSH starting dose >50±75 IU may result in ovarian
hyperstimulation in at least 30% of an unselected PCOS
population; (iii) it remains questionable if IVF with or without
in-vitro maturation of oocytes provides improved ef®cacy and
safety compared with ovulation induction strategies; and
(iv) classical induction of ovulation is a highly effective
treatment modality and there is still room for improvement
applying new compounds and prediction models, resulting in a
more individually tailored approach
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